A digital microfluidic platform for high yield CHO cell line detection and culture

用于高产 CHO 细胞系检测和培养的数字微流控平台

• 批准号: 559533-2020
• 负责人: Wheeler, Aaron
• 金额: $ 4.31万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=706818
• 关键词: digital; microfluidic; platform; yield; CHO

In this NSERC Alliance proposal, Sartorius Canada, Sanofi Pasteur, and the Wheeler research group at the University of Toronto propose to work together to explore the development of digital microfluidic technologies for lead candidate identification and screening of therapeutic protein production from a model cell line (Chinese Hamster Ovary, or "CHO" cells). We are an ideal team to pursue this project, as Sartorius Canada is a market leader in the development of instrumentation that is used in the production of therapeutic proteins, Sanofi Pasteur is one of the top vaccine-producers in the world, and the Wheeler group has a long track record in automating cell culture and analysis using the unique platform that is known as digital microfluidics (DMF). We propose to develop new DMF-enabled systems that allow for the optimization of CHO cell production of monoclonal antibodies, recombinant vaccine proteins, and other important bioproducts. The key deliverable of this work is a platform that could eventually serve as the basis for a Sartorius product that will allow end-users such as Sanofi Pasteur to automate CHO cell culture to identify high-performing cells and/or optimal media formulations which lead to the highest protein yield, which will increase efficiency and profitability. This application represents the beginning of what may eventually become an important Canadian story - the development of digital microfluidic systems for efficient protein production in CHO cells. We thank NSERC in advance for potential support of this nascent effort, which could lead to important benefits for Canadians and others around the world.

在这个NSERC联盟提案中，多伦多大学的Sartorius Canada，Sanofi Pasteur和Wheeler Research Group提议共同努力，以探索数字微流体技术的开发，用于从模型细胞系（中国Hamster Ovary Ovary Ovary或“ Cho Cho）中识别和筛选治疗蛋白质生产的铅候选和筛查）。我们是一个理想的团队，可以追求该项目，因为加拿大Sartorius是仪器开发的市场领导者，用于生产治疗性蛋白质，Sanofi Pasteur是世界上顶级的疫苗生产商之一，Wheeler Group在使用独特的细胞文化和分析中，使用独特的平台，众所周知，惠勒集团在自动化细胞文化和分析中具有很长的良好记录。我们建议开发新的支持DMF的系统，以优化单克隆抗体，重组疫苗蛋白和其他重要生物产生的CHO细胞产生。这项工作的关键可交付是一个平台，最终可以作为Sartorius产品的基础，该产品将允许诸如Sanofi Pasteur之类的最终用户自动化Cho Cell培养物自动化Cho Cell培养物，以鉴定高性能的细胞和/或最佳培养基配方，从而导致最高的蛋白质产量，从而提高效率和获利能力。该应用程序代表了最终成为重要的加拿大故事的开始 - 数字微流体系统的开发，用于CHO细胞中有效的蛋白质生产。我们事先感谢NSERC对这项新生努力的潜在支持，这可能会给加拿大人和世界其他人带来重要的好处。